Abbott Laboratories reported first quarter 2026 sales of US$11.16 billion, driven by solid contributions from its Medical Devices segment, and issued full year guidance pointing to mid single digit comparable sales growth. The company's shares have gained 5.62% over the past seven days and 5.24% over the past 30 days, though they remain down 22.83% year to date and have declined 26.67% over the past year. Analysts have a consensus price target of US$116.54, with estimates ranging from US$92.00 to US$135.00, suggesting the stock may be undervalued relative to its long-term earnings potential.
Abbott LaboratoriesAbbott reported Q1 sales of $11.16B and issued full-year guidance for mid single-digit comparable sales growth, with analysts suggesting the stock may be undervalued.